Wave Life Sciences USA

Wave Life Sciences is a clinical-stage RNA medicines biotechnology company that uses its PRISM platform, which combines stereopure oligonucleotide chemistry with machine learning, to design RNA-targeting medicines. Its pipeline includes RNA editing (ADAR-mediated), splicing, and silencing programs. These target genetically defined conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity. Its mission is to unlock the potential of the genome to transform human health.